Iota-carrageenan for COVID-19: real-time analysis of all 13 studies

Time 2022-07-19 12:59:06

Web Name: Iota-carrageenan for COVID-19: real-time analysis of all 13 studies

WebSite: http://www.c19ic.com

ID:252763

Keywords:

COVID,real,Iota,carrageenan

Description:

Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
HomeHomeCOVID-19 treatment studies for Iota-carrageenanCOVID-19 treatment studies for Iota-carragee..C19 studies: Iota-carragee..Iota-carragee..Select treatmentSelect treatmentTreatmentsTreatmentsAntiandrogens(meta)Lactoferrin(meta)Aspirin(meta)Melatonin(meta)Bamlaniv../e..(meta)Metformin(meta)Bebtelovimab(meta)Molnupiravir(meta)Bromhexine(meta)N-acetylcys..(meta)Budesonide(meta)Nigella Sativa(meta)Cannabidiol(meta)Nitazoxanide(meta)Casirivimab/i..(meta)Paxlovid(meta)Colchicine(meta)Peg.. Lambda(meta)Conv. Plasma(meta)Povidone-Iod..(meta)Curcumin(meta)Probiotics(meta)Diet(meta)Proxalutamide(meta)Ensitrelvir(meta)Quercetin(meta)Ensovibep(meta)Remdesivir(meta)Exercise(meta)Sleep(meta)Famotidine(meta)Sotrovimab(meta)Favipiravir(meta)Tixagev../c..(meta)Fluvoxamine(meta)Vitamin A(meta)Hydroxychlor..(meta)Vitamin C(meta)Iota-carragee..(meta)Vitamin D(meta)Ivermectin(meta)Zinc(meta)

---

Other TreatmentsGlobal AdoptionHomeShareTweetOutcomesOutcomesGlobal AdoptionAdoptionSubmit FeedbackFeedbackDownload ImageDownload ImageDownload ImageIota-carrageenan COVID-19 studies. Submit updates/corrections.Iota-carragee..AllDec 8
2021In VitroFröba et al., International Journal of Molecular Sciences, doi:10.3390/ijms222413202 (In Vitro)In VitroIota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and DeltaDetails In Vitro study of iota-, lambda-, and kappa-carrageenan sulfated polysaccharides extracted from red seaweed on SARS-CoV-2 Wuhan type and variants Alpha, Beta, Gamma and Delta, showing that all three carrageenan types had antiviral activit..Dec 8
2021Details Source PDF In VitroIn VitroIota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and DeltaFröba et al., International Journal of Molecular Sciences, doi:10.3390/ijms222413202 (In Vitro)In Vitro study of iota-, lambda-, and kappa-carrageenan sulfated polysaccharides extracted from red seaweed on SARS-CoV-2 Wuhan type and variants Alpha, Beta, Gamma and Delta, showing that all three carrageenan types had antiviral activity. Iota-carrageenan had comparable IC50 values against all variants. Authors conclude that iota-carrageenan might be effective for prophylaxis and treatment of SARS-CoV-2 for existing and potentially future variants.Fröba et al., 12/8/2021, peer-reviewed, 14 authors.In Vitro studies are an important part of preclinical research, however results may be very different in vivo.Share Tweet Submit Corrections or CommentsSep 7
2021N/AMorokutti-Kurz et al., International Journal of General Medicine, doi:10.2147/IJGM.S325861The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2Details Prospective study of 31 subjects analyzing iota-carrageenan concentration in saliva after using an iota-carrageenan containing lozenge, showing sufficient concentration to neutralize common respiratory viruses including SARS-CoV-2. For SA..Sep 7
2021Details Source PDF N/AN/AThe Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2Morokutti-Kurz et al., International Journal of General Medicine, doi:10.2147/IJGM.S325861Prospective study of 31 subjects analyzing iota-carrageenan concentration in saliva after using an iota-carrageenan containing lozenge, showing sufficient concentration to neutralize common respiratory viruses including SARS-CoV-2. For SARS-CoV-2, the IC90 was exceeded by 121-fold (p < 0.001). NCT04533906.Morokutti-Kurz et al., 9/7/2021, peer-reviewed, 12 authors, trial NCT04533906.Share Tweet Submit Corrections or CommentsJul 26
2021In VitroAlsaidi et al., Marine Drugs, doi:10.3390/md19080418 (In Vitro)In VitroGriffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral ModelDetails In Vitro and In Silico analysis showing SARS-CoV-2 antiviral activity of carageenan, and synergistic activity from the combination of carrageenan and griffithsin.Jul 26
2021Details Source PDF In VitroIn VitroGriffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral ModelAlsaidi et al., Marine Drugs, doi:10.3390/md19080418 (In Vitro)In Vitro and In Silico analysis showing SARS-CoV-2 antiviral activity of carageenan, and synergistic activity from the combination of carrageenan and griffithsin.Alsaidi et al., 7/26/2021, peer-reviewed, 12 authors.In Vitro studies are an important part of preclinical research, however results may be very different in vivo.Share Tweet Submit Corrections or CommentsJun 14
2021EarlyHemilä et al., Pharmacology Research and Perspectives, doi:10.1002/prp2.810Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial dataDetails Individual patient data meta analysis of two RCTs showing nasal iota-carrageenan improved recovery rate and shortened the duration of long colds. There was a 71% reduction in the risk of long colds (>20 days). The increase in recovery rat..Jun 14
2021Details Source PDF Early treatment studyEarly treatment studyCarrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial dataHemilä et al., Pharmacology Research and Perspectives, doi:10.1002/prp2.810Individual patient data meta analysis of two RCTs showing nasal iota-carrageenan improved recovery rate and shortened the duration of long colds. There was a 71% reduction in the risk of long colds (>20 days). The increase in recovery rate was 139% for coronavirus infections, 119% for influenza A infections, and 70% for rhinovirus infections.Hemilä et al., 6/14/2021, peer-reviewed, 2 authors.Share Tweet Submit Corrections or CommentsApr 28
2021EarlySchütz et al., American Journal of Physiology: Lung Cellular and Molecular Physiology, doi:10.1152/ajplung.00552.2020Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial culturesDetails In Vitro study showing that carrageenan-containing nose spray and mouth spray inhibit SARS-CoV-2 in human airway epithelial cultures.Apr 28
2021Details Source PDF Early treatment studyEarly treatment studyCarrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial culturesSchütz et al., American Journal of Physiology: Lung Cellular and Molecular Physiology, doi:10.1152/ajplung.00552.2020In Vitro study showing that carrageenan-containing nose spray and mouth spray inhibit SARS-CoV-2 in human airway epithelial cultures.Schütz et al., 4/28/2021, peer-reviewed, 12 authors.Share Tweet Submit Corrections or CommentsApr 27
2021In VitroVarese et al., bioRxiv, doi:10.1101/2021.04.27.441512 (Preprint) (In Vitro)In VitroIota-carrageenan prevents the replication of SARS-CoV-2 on an in vitro respiratory epithelium modelDetails In Vitro Calu-3 (human respiratory epithelial cell line) study showing that iota-carrageenan inhibits SARS-CoV-2.Apr 27
2021Details Source PDF In VitroIn VitroIota-carrageenan prevents the replication of SARS-CoV-2 on an in vitro respiratory epithelium modelVarese et al., bioRxiv, doi:10.1101/2021.04.27.441512 (Preprint) (In Vitro)In Vitro Calu-3 (human respiratory epithelial cell line) study showing that iota-carrageenan inhibits SARS-CoV-2.Varese et al., 4/27/2021, preprint, 5 authors.In Vitro studies are an important part of preclinical research, however results may be very different in vivo.Share Tweet Submit Corrections or CommentsApr 15
2021PrEPPEPFigueroa et al., International Journal of General Medicine, doi:10.2147/IJGM.S328486 (preprint 4/15/2021)symp. case, ↓80.2%, p=0.03Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02)Details Prophylaxis RCT with 394 healthcare workers, 196 treated with iota-carrageenan, showing significantly lower symptomatic cases with treatment. There were no deaths or hospitalizations. There was a significant number of PCR- symptomatic cas..Apr 15
2021Details Source PDF Prophylaxis studyProphylaxis studyEfficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02)Figueroa et al., International Journal of General Medicine, doi:10.2147/IJGM.S328486 (preprint 4/15/2021)Prophylaxis RCT with 394 healthcare workers, 196 treated with iota-carrageenan, showing significantly lower symptomatic cases with treatment. There were no deaths or hospitalizations. There was a significant number of PCR- symptomatic cases (7.6% treatment and 8.6% control). The two treatment cases occurred shortly after randomization - infection may have occurred before the start of treatment. CARR-COV-02. NCT04521322.risk of symptomatic case, 80.2% lower, RR 0.20, p = 0.03, treatment 2 of 196 (1.0%), control 10 of 198 (5.1%), NNT 25, OR converted to RR.Figueroa et al., 4/15/2021, Double Blind Randomized Controlled Trial, Argentina, South America, peer-reviewed, 18 authors, trial NCT04521322.Share Tweet Submit Corrections or CommentsFeb 17
2021In VitroMorokutti-Kurz et al., PLoS ONE, doi:10.1371/journal.pone.0237480 (In Vitro)In VitroIota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitroDetails In Vitro study showing that SARS-CoV-2 is inhibited by iota-carrageenan in a dose dependent manner and to the same extent as other respiratory viruses for which a clinical benefit has been proven. Authors note that clinical data and post ..Feb 17
2021Details Source PDF In VitroIn VitroIota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitroMorokutti-Kurz et al., PLoS ONE, doi:10.1371/journal.pone.0237480 (In Vitro)In Vitro study showing that SARS-CoV-2 is inhibited by iota-carrageenan in a dose dependent manner and to the same extent as other respiratory viruses for which a clinical benefit has been proven. Authors note that clinical data and post market surveillance data show that iota-carrageenan is well-tolerated with very low reported adverse events.Morokutti-Kurz et al., 2/17/2021, peer-reviewed, 8 authors.In Vitro studies are an important part of preclinical research, however results may be very different in vivo.Share Tweet Submit Corrections or CommentsJan 11
2021PrEPPEPChahla et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001433m/s case, ↓95.2%, p=0.002A randomized trial - intensive treatment based in ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare agentsDetails Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina, 117 healthcare workers treated with ivermectin and iota-carrageenan, and 117 controls, showing significantly lower cases with treatment. There were no moderate/severe cases..Jan 11
2021Details Source PDF Prophylaxis studyProphylaxis studyA randomized trial - intensive treatment based in ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare agentsChahla et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001433Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina, 117 healthcare workers treated with ivermectin and iota-carrageenan, and 117 controls, showing significantly lower cases with treatment. There were no moderate/severe cases with treatment vs. 10 in the control group. There were 4 cases with treatment (all mild) vs. 25 for the control group. NCT04701710.risk of moderate/severe case, 95.2% lower, RR 0.05, p = 0.002, treatment 0 of 117 (0.0%), control 10 of 117 (8.5%), NNT 12, relative risk is not 0 because of continuity correction due to zero events, moderate/severe COVID-19.risk of case, 84.0% lower, RR 0.16, p = 0.004, treatment 4 of 117 (3.4%), control 25 of 117 (21.4%), NNT 5.6, adjusted, OR converted to RR, all cases.Chahla et al., 1/11/2021, Randomized Controlled Trial, Argentina, South America, peer-reviewed, 11 authors, this trial uses multiple treatments in the treatment arm (combined with ivermectin) - results of individual treatments may vary, trial NCT04701710.Share Tweet Submit Corrections or CommentsDec 29
2020ReviewHans et al., Bioresource Technology Reports, doi:10.1016/j.biteb.2020.100623 (Review)reviewAntiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini reviewDetails Review of the antiviral activity of marine sulfated polysaccharides including carrageenan, and the mechanisms of action for inhibiting different stages of viral infection.Dec 29
2020Details Source PDF ReviewReviewAntiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini reviewHans et al., Bioresource Technology Reports, doi:10.1016/j.biteb.2020.100623 (Review)Review of the antiviral activity of marine sulfated polysaccharides including carrageenan, and the mechanisms of action for
inhibiting different stages of viral infection.Hans et al., 12/29/2020, peer-reviewed, 3 authors.Share Tweet Submit Corrections or CommentsNov 17
2020PrEPPEPCarvallo et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007cases, ↓99.9%, p<0.0001Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health PersonnelDetails Prophylaxis study using ivermectin and iota-carrageenan showing 0 of 788 cases from treated healthcare workers, compared to 237 of 407 control. The authors later reported that carrageenan is not necessary in this protocol .Nov 17
2020Details Source PDF Prophylaxis studyProphylaxis studyStudy of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health PersonnelCarvallo et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007Prophylaxis study using ivermectin and iota-carrageenan showing 0 of 788 cases from treated healthcare workers, compared to 237 of 407 control.The authors later reported that carrageenan is not necessary in this protocol [youtube.com].1.youtube.com,https://www.youtube.com/watch?v=CB6Bvi_g-w8.risk of case, 99.9% lower, RR 0.001, p < 0.001, treatment 0 of 788 (0.0%), control 237 of 407 (58.2%), NNT 1.7, relative risk is not 0 because of continuity correction due to zero events.Excluded in after exclusion results of meta analysis:concern about potential data issues.Carvallo et al., 11/17/2020, prospective, Argentina, South America, peer-reviewed, 4 authors, this trial uses multiple treatments in the treatment arm (combined with ivermectin) - results of individual treatments may vary.Share Tweet Submit Corrections or CommentsAug 24
2020In VitroSong et al., Food & Function, doi:10.1039/D0FO02017F (In Vitro)In VitroInhibitory activities of marine sulfated polysaccharides against SARS-CoV-2Details In Vitro study showing significant antiviral activity of marine sulfated polysaccharides iota-carrageenan, sea cucumber sulfated polysaccharide, and fucoidan.Aug 24
2020Details Source PDF In VitroIn VitroInhibitory activities of marine sulfated polysaccharides against SARS-CoV-2Song et al., Food & Function, doi:10.1039/D0FO02017F (In Vitro)In Vitro study showing significant antiviral activity of marine sulfated polysaccharides iota-carrageenan, sea cucumber sulfated polysaccharide, and fucoidan.Song et al., 8/24/2020, peer-reviewed, 10 authors.In Vitro studies are an important part of preclinical research, however results may be very different in vivo.Share Tweet Submit Corrections or CommentsAug 21
2020In VitroBansal et al., PLoS ONE, doi:10.1371/journal.pone.0259943 (preprint 8/21/20) (In Vitro)In VitroIota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell cultureDetails In Vitro study showing that iota-carrageenan in concentrations as low as 6 µg/mL (easily achievable with existing nasal sprays) inhibits SARS-CoV-2 in Vero cell cultures.Aug 21
2020Details Source PDF In VitroIn VitroIota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell cultureBansal et al., PLoS ONE, doi:10.1371/journal.pone.0259943 (preprint 8/21/20) (In Vitro)In Vitro study showing that iota-carrageenan in concentrations as low as 6 µg/mL (easily achievable with existing nasal sprays) inhibits SARS-CoV-2 in Vero cell cultures.Bansal et al., 8/21/2020, peer-reviewed, 7 authors.In Vitro studies are an important part of preclinical research, however results may be very different in vivo.Share Tweet Submit Corrections or CommentsJun 29
2020In SilicoSattari et al., Research Square, doi:10.21203/rs.3.rs-37994/v1 (Preprint)In SilicoRepositioning Therapeutics for COVID-19: Virtual Screening of the Potent Synthetic and Natural Compounds as SARS-CoV-2 3CLpro InhibitorsDetails In Silico study identifying kappa-carrageenan and other compounds as potential candidates for SARS-CoV-2 inhibition.Jun 29
2020Details Source PDF In SilicoIn SilicoRepositioning Therapeutics for COVID-19: Virtual Screening of the Potent Synthetic and Natural Compounds as SARS-CoV-2 3CLpro InhibitorsSattari et al., Research Square, doi:10.21203/rs.3.rs-37994/v1 (Preprint)In Silico study identifying kappa-carrageenan and other compounds as potential candidates for SARS-CoV-2 inhibition.Sattari et al., 6/29/2020, preprint, 3 authors.In Silico studies are an important part of preclinical research, however results may be very different in vivo.Share Tweet Submit Corrections or Comments2014EarlyKoenighofer et al., Multidisciplinary Respiratory Medicine, doi:10.1186/2049-6958-9-57Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trialsDetails Analysis of 2 RCTs concluding that carrageenan nasal spray reduced duration of virus-confirmed common colds, increased viral clearance, and reduced relapses.2014Details Source PDF Early treatment studyEarly treatment studyCarrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trialsKoenighofer et al., Multidisciplinary Respiratory Medicine, doi:10.1186/2049-6958-9-57Analysis of 2 RCTs concluding that carrageenan nasal spray reduced duration of virus-confirmed common colds, increased viral clearance, and reduced relapses.Koenighofer et al., 1/1/2014, peer-reviewed, 8 authors.Share Tweet Submit Corrections or CommentsPlease send us corrections, updates, or comments. Vaccines andtreatments are both valuable and complementary. All practical, effective, andsafe means should be used. No treatment, vaccine, or intervention is 100%available and effective for all current and future variants. Denying theefficacy of any method increases mortality, morbidity, collateral damage, andthe risk of endemic status. We do not provide medical advice. Before takingany medication, consult a qualified physician who can provide personalizedadvice and details of risks and benefits based on your medical history andsituation. FLCCC and WCHprovide treatment protocols. Thanks for your feedback! Please search before submitting papers and notethat studies are listed under the date they were first available, which may bethe date of an earlier preprint.SubmitShareTweet@CovidAnalysisFAQPublic domain CC0 1.0

TAGS:COVID real Iota carrageenan

<<< Thank you for your visit >>>

Hot Websites